These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
588 related articles for article (PubMed ID: 9626234)
1. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages? Andrieu JM; Colonna P J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234 [No Abstract] [Full Text] [Related]
2. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796 [TBL] [Abstract][Full Text] [Related]
3. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages? Diehl V; Fuchs M; Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996 [TBL] [Abstract][Full Text] [Related]
4. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Santoro A; Viviani S; Villarreal CJ; Bonfante V; Delfino A; Valagussa P; Bonadonna G Cancer Treat Rep; 1986 Mar; 70(3):343-8. PubMed ID: 2420444 [TBL] [Abstract][Full Text] [Related]
5. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease. Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754 [TBL] [Abstract][Full Text] [Related]
6. Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-protocol. Hakvoort-Cammel FG; Buitendijk S; van den Heuvel-Eibrink M; Hählen K Pediatr Blood Cancer; 2004 Jul; 43(1):8-16. PubMed ID: 15170884 [TBL] [Abstract][Full Text] [Related]
7. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ; N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708 [TBL] [Abstract][Full Text] [Related]
8. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718 [TBL] [Abstract][Full Text] [Related]
9. Pediatric Hodgkin's disease. Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795 [TBL] [Abstract][Full Text] [Related]
10. [Successful chemotherapy of cancer. Remission of Hodgkin's disease. IV]. Lopez M Clin Ter; 2001; 152(3):203-6. PubMed ID: 11692542 [No Abstract] [Full Text] [Related]
11. MOPP, ABVD, or both to treat Hodgkin's disease. Aisenberg AC N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680765 [No Abstract] [Full Text] [Related]
12. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study. Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487 [TBL] [Abstract][Full Text] [Related]
13. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center]. Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222 [TBL] [Abstract][Full Text] [Related]
14. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related]
15. Advanced Hodgkin's disease: ABVD is better, yet is not good enough! Diehl V J Clin Oncol; 2003 Feb; 21(4):583-5. PubMed ID: 12586791 [No Abstract] [Full Text] [Related]
17. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute. Bonadonna G; Viviani S; Bonfante V; Gianni AM; Valagussa P Eur J Cancer; 2005 May; 41(7):998-1006. PubMed ID: 15862748 [TBL] [Abstract][Full Text] [Related]
18. [Cancer of the testis after Hodgkin's disease. Apropos of 2 cases]. Robert M; Averous M; Lavabre-Bertrand T; Iborra F; Chevallier P; Rebillard X; Guiter J; Grasset D J Urol (Paris); 1992; 98(3):178-80. PubMed ID: 1282922 [TBL] [Abstract][Full Text] [Related]
19. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP. Anselmo AP; Cartoni C; Bellantuono P; Maurizi-Enrici R; Aboulkair N; Ermini M Haematologica; 1990; 75(2):155-8. PubMed ID: 1694156 [TBL] [Abstract][Full Text] [Related]
20. Male infertility caused by the chemotherapy of Hodgkin's disease: MOPP versus ABVD. Ragni G; Lombardi C; Santoro A; Bestetti O; Wyssling H Acta Eur Fertil; 1983; 14(3):221-2. PubMed ID: 6199937 [No Abstract] [Full Text] [Related] [Next] [New Search]